Prophylactic Dexamethasone Before Infliximab in Moderate-to-Severe IBD

NCT07385131 | Recruiting

• 1 other identifier: 2025-0744
• Study Type: observational
• Target: 300
• Locations: 1 country
• Sites: 1

Brief Summary

This comparative observational cohort clinical study aims to investigate the necessity of premedication for allergy prevention prior to infliximab injection, and is designed to evaluate whether non-routine administration of dexamethasone before intravenous infusion of infliximab yields greater benefits than routine prophylactic medication in patients with moderate-to-severe inflammatory bowel disease (IBD). This study is designed to optimize the prophylactic strategy prior to Infliximab treatment and advocate for risk stratification-based individualized prophylaxis regimens to avoid hormonal abuse. Additionally, it will construct a risk score using biomarkers to accurately identify high-risk populations in need of prophylaxis and establish a corresponding predictive model. The study is also intended to reduce the use of unnecessary medications, shorten infusion duration and alleviate the medical burden. It is expected to provide targeted clinical support during the early stage of the disease or the course of treatment, improve the efficacy and precision of individualized treatment for patients, and reduce the physical, psychological and economic burdens caused by ineffective treatment.

Conditions

Inflammatory Bowel Disease (IBD); CD - Crohn's Disease; UC - Ulcerative Colitis

Keywords

Infliximab; Dexamethasone; Preventive medication; Infusion reaction

Outcome Measures

Primary Outcomes (1)

• The proportion of patients experiencing infusion reactions

  The rate of patients experiencing acute moderate-to-severe infusion reactions related to infliximab during the first four administrations

  up to the fourth administration of infliximab

Secondary Outcomes (3)

• Concentration of drug and antibody

  the 4th and 6th administrations of infliximab

• Severe infusion reactions

  through study completion

• Hormone-related side effects

  through study completion

Study Arms (2)

TEST

If there was no allergic reaction during the previous infusion of infliximab, no anti-allergic medication needs to be used before the next infusion.

DEX

Before each infusion of infliximab, 5mg of dexamethasone was administered intravenously.

Drug: Dexamethasone (IV)

Interventions

Dexamethasone (IV) DRUG

Before each infusion of infliximab, 5mg of dexamethasone was administered intravenously or an equal volume of normal saline was injected.

DEX

Eligibility Criteria

• Age: 14 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with moderate to severe inflammatory bowel disease who are scheduled to receive infliximab treatment for the first time within 2 weeks

You may qualify if:

• Aged 14 to 80 years.
• Confirmed cases of inflammatory bowel disease (IBD) with a definitive diagnosis of Crohn's disease (CD) or ulcerative colitis (UC), based on the diagnostic criteria specified in the Chinese Guidelines for the Diagnosis and Treatment of Crohn's Disease (Guangzhou, 2023) and the Chinese Guidelines for the Diagnosis and Treatment of Ulcerative Colitis (Xi'an, 2023). The diagnosis shall be made by comprehensive analysis of clinical manifestations, laboratory tests, imaging examinations, endoscopic examinations and histopathological findings, with infectious colitis and other non-infectious colitis ruled out.
• Moderate to severe CD: for adults aged 18 years and above, baseline Crohn's Disease Activity Index (CDAI) score \>220 or Harvey-Bradshaw Index (HBI) score ≥5; for adolescents aged 14 to 17 years, baseline Pediatric Crohn's Disease Activity Index (PCDAI) score ≥31. Or moderate to severe UC: for adults aged 18 years and above, baseline Mayo score ≥6; for adolescents aged 14 to 17 years, baseline Pediatric Ulcerative Colitis Activity Index (PUCAI) score ≥36.
• Not receiving immunosuppressant therapy (e.g., azathioprine) at present, with no plan to add such medications within the next two months.
• Current glucocorticoid dosage ≤ 10 tablets, and a definite plan has been made for tapering down the dosage to complete discontinuation within the next two months.
• Planned to receive the first dose of infliximab within the next two weeks.

You may not qualify if:

• Patients with severe disease who, as judged by the attending clinician, require biological agent intensification therapy, switch therapy or elective surgery within 2 months, such as those with obvious stenosis, perforation, fistula and other conditions leading to obstruction, hemorrhage, infection, etc.
• Patients at high risk of infusion reactions, including those with a history of any biological agent-related infusion reactions, or a history of allergy to any drugs such as penicillins, cephalosporins, sulfonamides, non-steroidal anti-inflammatory drugs (NSAIDs), contrast media, etc.
• Patients with a definite history of food allergy, as well as a past history of asthma or urticaria.
• Patients on chronic daily use of antihistamine antiallergic drugs such as loratadine, cetirizine, diphenhydramine, chlorpheniramine maleate tablets, terfenadine, etc.
• Patients with relative contraindications to biological agents, such as active tuberculosis with positive chest X-ray, strongly positive purified protein derivative (PPD) skin test or positive T-SPOT test; a history of myocardial infarction, heart failure or demyelinating neurological diseases in the past 5 years, etc.
• Patients with relative contraindications to glucocorticoids, such as active tuberculosis, severe infection, gastrointestinal ulcer, etc.
• Patients currently suffering from solid tumors, with a past history of lymphoma or melanoma, or undergoing chemotherapy or radiotherapy.
• Patients complicated with massive gastrointestinal hemorrhage, severe hepatic and renal dysfunction, active bacterial or viral infection, shock, intractable vomiting, severe malabsorption syndrome, etc.
• Patients with psychiatric disorders or insufficient educational level to fully understand the study content.
• Pregnant or lactating patients.
• Patients with severe hemodynamic and vital sign instability, or those with rapidly progressive or end-stage diseases.

Sponsors & Collaborators

• First Affiliated Hospital of Wenzhou Medical University: collaborator
• West China Hospital: collaborator
• Second Affiliated Hospital, School of Medicine, Zhejiang University: lead
• The Fourth Affiliated Hospital of Zhejiang University School of Medicine: collaborator
• Second Affiliated Hospital of Xi'an Jiaotong University: collaborator
• Huzhou Central Hospital: collaborator
• Taizhou Enze Medical Center Group: collaborator
• Lishui Country People's Hospital: collaborator
• Jinhua People's Hospital: collaborator
• Ningbo Medical Center Lihuili Hospital: collaborator
• Affiliated Wenling Hospital of Wenzhou Medical University: collaborator
• People's Hospital of Quzhou: collaborator
• Taizhou Municipal Center for Disease Control and Prevention: collaborator
• Second Affiliated Hospital of Wenzhou Medical University: collaborator

Study Sites (1)

Second Affiliated Hospital, School of Medicine, Zhejiang University

Hangzhou, Zhejiang, 310000, China

RECRUITING

MeSH Terms

Conditions

Inflammatory Bowel Diseases; Crohn Disease; Colitis, Ulcerative

Interventions

Dexamethasone

Condition Hierarchy (Ancestors)

Gastroenteritis; Gastrointestinal Diseases; Digestive System Diseases; Intestinal Diseases; Colitis; Colonic Diseases

Intervention Hierarchy (Ancestors)

Pregnadienetriols; Pregnadienes; Pregnanes; Steroids; Fused-Ring Compounds; Polycyclic Compounds; Steroids, Fluorinated

Central Study Contacts

Yan Chen

CONTACT

86+13757118653; chenyan72_72@zju.edu.cn

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: January 27, 2026
• First Posted: February 3, 2026
• Study Start: October 8, 2025
• Primary Completion (Estimated): December 31, 2028
• Study Completion (Estimated): December 31, 2029
• Last Updated: February 3, 2026

Record last verified: 2026-01

Locations

CN (1)